이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Boston Scientific 대차 대조표 상태
재무 상태 기준 확인 5/6
Boston Scientific 의 총 주주 지분은 $20.2B 이고 총 부채는 $10.6B, 이는 부채 대 자기자본 비율을 52.6% 로 가져옵니다. 총자산과 총부채는 각각 $36.7B 및 $16.5B 입니다. Boston Scientific 의 EBIT는 $2.5B 이며 이자보상배율은 10.2 입니다. $2.3B 의 현금 및 단기 투자금을 보유하고 있습니다.
주요 정보
51.3%
부채 비율
US$10.57b
부채
| 이자 보상 비율 | 10.7x |
| 현금 | US$2.91b |
| 주식 | US$20.61b |
| 총 부채 | US$16.50b |
| 총 자산 | US$37.11b |
최근 재무 상태 업데이트
Is Boston Scientific (NYSE:BSX) Using Too Much Debt?
May 10
Is Boston Scientific (NYSE:BSX) A Risky Investment?
Feb 02Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?
Nov 03Boston Scientific (NYSE:BSX) Seems To Use Debt Quite Sensibly
Jul 25Here's Why Boston Scientific (NYSE:BSX) Can Manage Its Debt Responsibly
Apr 18Recent updates
Boston Scientific Corporation's (NYSE:BSX) P/E Still Appears To Be Reasonable
Sep 09A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Aug 23The Strong Earnings Posted By Boston Scientific (NYSE:BSX) Are A Good Indication Of The Strength Of The Business
Aug 08Boston Scientific Q2 Earnings Preview: Can The Rally Continue?
Jul 17Here's Why We Think Boston Scientific (NYSE:BSX) Is Well Worth Watching
Jul 05Should You Investigate Boston Scientific Corporation (NYSE:BSX) At US$77.00?
Jun 21Boston Scientific Has Become A Standout Growth Story In Med-Tech
Jun 13Why We're Not Concerned About Boston Scientific Corporation's (NYSE:BSX) Share Price
Jun 08Is Boston Scientific (NYSE:BSX) Using Too Much Debt?
May 10Boston Scientific (NYSE:BSX) Is Reinvesting At Lower Rates Of Return
Apr 22Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash
Apr 05A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Mar 26We Ran A Stock Scan For Earnings Growth And Boston Scientific (NYSE:BSX) Passed With Ease
Feb 29What You Can Learn From Boston Scientific Corporation's (NYSE:BSX) P/E
Feb 15Is Boston Scientific (NYSE:BSX) A Risky Investment?
Feb 02Boston Scientific (NYSE:BSX) Could Be Struggling To Allocate Capital
Jan 19Boston Scientific: Portfolio Updates Driving Top-Line Growth
Jan 17Boston Scientific: Continued M&A Drives More Growth
Jan 10Is Boston Scientific Corporation (NYSE:BSX) Worth US$56.1 Based On Its Intrinsic Value?
Dec 04Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?
Nov 03Boston Scientific: Delivering Strong Growth, But Sector Derating Is A Big Issue
Oct 30ADVENT Offers Up An Early Present For Boston Scientific Investors
Aug 28Estimating The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Aug 24Boston Scientific (NYSE:BSX) Seems To Use Debt Quite Sensibly
Jul 25Boston Scientific Remains Operationally Sound But May Have Limited Upside
Jul 14Investors Could Be Concerned With Boston Scientific's (NYSE:BSX) Returns On Capital
Jul 10Boston Scientific Corporation (NYSE:BSX) Shares Could Be 29% Above Their Intrinsic Value Estimate
May 21Here's Why Boston Scientific (NYSE:BSX) Can Manage Its Debt Responsibly
Apr 18Returns On Capital At Boston Scientific (NYSE:BSX) Paint A Concerning Picture
Apr 03Boston Scientific Stands Out With Strong, Diversified Growth Profile
Feb 15재무 상태 분석
단기부채: BSX 의 단기 자산 ( $8.2B )이 단기 부채( $4.9B ).
장기 부채: BSX 의 단기 자산( $8.2B )은 장기 부채( $11.6B ).
부채 대 자본 내역 및 분석
부채 수준: BSX 의 순부채 대 자기자본 비율( 37.1% )은 satisfactory로 간주됩니다.
부채 감소: BSX 의 부채 대 자기자본 비율은 지난 5년간 99.9% 에서 52.6% 로 감소했습니다.
부채 범위: BSX 의 부채는 영업 현금 흐름 ( 23.3% )에 의해 잘 충당되었습니다.
이자 보장: BSX 의 부채에 대한 이자 지급은 EBIT( 10.2 x 적용 범위)로 잘 충당됩니다.